Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk

Paul K. Mills, Deborah G. Riordan, Rosemary D Cress, David F. Goldsmith

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Risk of epithelial ovarian cancer (EOC) attendant to use of hormone replacement therapy (HRT) was evaluated in a population-based case-control study of newly diagnosed EOC cases (n = 256) and randomly selected population controls (n = 1122). Telephone interviews were conducted to obtain information on history of HRT and several other covariates. Multivariate adjusted odds ratio (OR) and 95% confidence intervals (CI) were derived from unconditional logistic regression. The OR for ever use of HRT was 1.39 (95% CI: 1.01-1.93) compared to never use. Long-term use (>10 years) increased risk (OR: 1.62, CI: 1.05-2.50) although the trend p-value for duration of use was of only borderline significance (p = 0.08). The relationship was stronger in women without hysterectomy (OR: 1.66, 95% CI: 1.14-2.41) or tubal ligation (OR: 1.56, 95% CI: 1.08-2.26). In this study, use of HRT is associated with an increased risk of EOC.

Original languageEnglish (US)
Pages (from-to)124-132
Number of pages9
JournalCancer Detection and Prevention
Volume29
Issue number2
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Hormone Replacement Therapy
Odds Ratio
Confidence Intervals
Tubal Sterilization
Population Control
Hysterectomy
Ovarian epithelial cancer
Case-Control Studies
Logistic Models
Interviews
Population

Keywords

  • Epidemiology
  • Gynecologic cancer
  • Hormone replacement therapy
  • Risk factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. / Mills, Paul K.; Riordan, Deborah G.; Cress, Rosemary D; Goldsmith, David F.

In: Cancer Detection and Prevention, Vol. 29, No. 2, 2005, p. 124-132.

Research output: Contribution to journalArticle

Mills, Paul K. ; Riordan, Deborah G. ; Cress, Rosemary D ; Goldsmith, David F. / Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. In: Cancer Detection and Prevention. 2005 ; Vol. 29, No. 2. pp. 124-132.
@article{2201125625a54ef1a4bdf68d99bcf929,
title = "Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk",
abstract = "Risk of epithelial ovarian cancer (EOC) attendant to use of hormone replacement therapy (HRT) was evaluated in a population-based case-control study of newly diagnosed EOC cases (n = 256) and randomly selected population controls (n = 1122). Telephone interviews were conducted to obtain information on history of HRT and several other covariates. Multivariate adjusted odds ratio (OR) and 95{\%} confidence intervals (CI) were derived from unconditional logistic regression. The OR for ever use of HRT was 1.39 (95{\%} CI: 1.01-1.93) compared to never use. Long-term use (>10 years) increased risk (OR: 1.62, CI: 1.05-2.50) although the trend p-value for duration of use was of only borderline significance (p = 0.08). The relationship was stronger in women without hysterectomy (OR: 1.66, 95{\%} CI: 1.14-2.41) or tubal ligation (OR: 1.56, 95{\%} CI: 1.08-2.26). In this study, use of HRT is associated with an increased risk of EOC.",
keywords = "Epidemiology, Gynecologic cancer, Hormone replacement therapy, Risk factors",
author = "Mills, {Paul K.} and Riordan, {Deborah G.} and Cress, {Rosemary D} and Goldsmith, {David F.}",
year = "2005",
doi = "10.1016/j.cdp.2004.11.002",
language = "English (US)",
volume = "29",
pages = "124--132",
journal = "Cancer Epidemiology",
issn = "1877-7821",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk

AU - Mills, Paul K.

AU - Riordan, Deborah G.

AU - Cress, Rosemary D

AU - Goldsmith, David F.

PY - 2005

Y1 - 2005

N2 - Risk of epithelial ovarian cancer (EOC) attendant to use of hormone replacement therapy (HRT) was evaluated in a population-based case-control study of newly diagnosed EOC cases (n = 256) and randomly selected population controls (n = 1122). Telephone interviews were conducted to obtain information on history of HRT and several other covariates. Multivariate adjusted odds ratio (OR) and 95% confidence intervals (CI) were derived from unconditional logistic regression. The OR for ever use of HRT was 1.39 (95% CI: 1.01-1.93) compared to never use. Long-term use (>10 years) increased risk (OR: 1.62, CI: 1.05-2.50) although the trend p-value for duration of use was of only borderline significance (p = 0.08). The relationship was stronger in women without hysterectomy (OR: 1.66, 95% CI: 1.14-2.41) or tubal ligation (OR: 1.56, 95% CI: 1.08-2.26). In this study, use of HRT is associated with an increased risk of EOC.

AB - Risk of epithelial ovarian cancer (EOC) attendant to use of hormone replacement therapy (HRT) was evaluated in a population-based case-control study of newly diagnosed EOC cases (n = 256) and randomly selected population controls (n = 1122). Telephone interviews were conducted to obtain information on history of HRT and several other covariates. Multivariate adjusted odds ratio (OR) and 95% confidence intervals (CI) were derived from unconditional logistic regression. The OR for ever use of HRT was 1.39 (95% CI: 1.01-1.93) compared to never use. Long-term use (>10 years) increased risk (OR: 1.62, CI: 1.05-2.50) although the trend p-value for duration of use was of only borderline significance (p = 0.08). The relationship was stronger in women without hysterectomy (OR: 1.66, 95% CI: 1.14-2.41) or tubal ligation (OR: 1.56, 95% CI: 1.08-2.26). In this study, use of HRT is associated with an increased risk of EOC.

KW - Epidemiology

KW - Gynecologic cancer

KW - Hormone replacement therapy

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=17044432658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044432658&partnerID=8YFLogxK

U2 - 10.1016/j.cdp.2004.11.002

DO - 10.1016/j.cdp.2004.11.002

M3 - Article

C2 - 15829372

AN - SCOPUS:17044432658

VL - 29

SP - 124

EP - 132

JO - Cancer Epidemiology

JF - Cancer Epidemiology

SN - 1877-7821

IS - 2

ER -